bluuebunny/crossref_metadata_2025_split huggingface dataset:
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
Authors: Topalian Suzanne Louise , Brahmer Julie R. , Hodi F. Stephen , McDermott David F. , Smith David C. , Gettinger Scott N. , Taube Janis M. , Drake Charles G. , Pardoll Drew M. , Antonia Scott , Spigel David R. , Atkins Michael B. , Lawrence Donald P. , McDonald Dan , Jure-Kunkel Maria , Korman Alan , Kollia Georgia , Gupta Ashok Kumar , Wigginton Jon , Sznol Mario 
Published: March 2020

CRA2509 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
Authors: Smith Ellen M. Lavoie , Pang Herbert , Cirrincione Constance , Fleishman Stewart Barry , Paskett Electra D. , Fadul Camilo E. , Knox Chetaye , Shapiro Charles L. , Gilman Paul ,   Cancer and Leukemia Group B
Published: March 2020

CRA9013 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Analysis of correlation between weight at diagnosis, weight gain after breast cancer treatment, and recurrence in women with early-stage breast cancer (EBC).
Authors: Fedele Palma , Lapolla Assunta Maria , Orlando Laura , Schiavone Paola , Nacci Angelo , Marino Antonella , Cinefra Margherita , Calvani Nicola , Ardizzone Antonino , De Pasquale Maria , Cinieri Saverio 
Published: March 2020

e11001 Background: Overweight at the time of EBC diagnosis has been linked frequently to poorer survival in most studies and some evidence suggests that women who gain weight after breast cancer diagnosis are at increased risk of cancer recurrence and death. Most previous studies on this topic have relied on retrospective chart reviews. The aim of this prospective, observational, single-center study is to determine whether weight at diagnosis and weight gain after EBC treatment can be predictive of BC recurrence. Methods: From December 1990 to January 2012, the study included atotal of 311 EBC patients (stage I-IIIa).We assessed weight and body mass index (BMI=kg/m2) at baseline (≤ 1 month after surgery) and 24 months after completion of treatment (chemotherapy ± radiotherapy). The chi square test (X2) was conducted to determine if a significant correlation exists between BC recurrence and 3 categories of BMI at diagnosis (lean weight: BMI <25; overweight: BMI 25-30; obese: BMI >25) and BC recurrence and weight changes after EBC treatment (loss of <1 kg/m2; loss of ≥ 1 kg/m2; gain of <2kg/m2; gain of >2 kg/m2). Results: Median age was 56 years (range28-81); 68% of patients were postmenopausal, stage I-II in 88%; ER+/PGR+ in 66%; ER+/PGR- in 12%; HER2+ in 14%; 72% underwent conservative surgery+radiotherapy; 57% received chemotherapy (CT) and 78% received endocrine therapy alone or after CT. Median BMI at diagnosis was 27.03, after treatment 28.04. After a median follow-up of 13 years 104 patients recurred. Statistical analysis is reported in the table. Conclusions: Our findings show that EBC patients gain weight after treatment. No significant correlation was found between weight at diagnosis, weight changes after EBC treatment and recurrence. At ASCO meeting we will report results of the prognostic associations of baseline biological features, menopausal status and comorbid disease. [Table: see text]
Decline in physical functioning in first 2 years after breast cancer diagnosis to predict survival in older women.
Authors: Sehl Mary Elizabeth , Lu Xiang , Silliman Rebecca A , Ganz Patricia A. 
Published: March 2020

e11003 Background: Breast cancer patients often experience a decline in physical functioning following cancer diagnosis. Although most patients recover after treatment, some patients do not. These changes may be magnified in older women with comorbid conditions and could impact survival outcomes. Methods: We used longitudinal data from a prospective cohort study of women 65+ years of age, recruited shortly after diagnosis of early stage breast cancer, to examine changes in self-reported physical functioning measured with the Physical Function Index (PF-10) of the Medical Outcomes Study Short Form-36 (SF-36). Outcomes were constructed for small (0.2 SD), medium (0.5 SD), and large (0.8 SD) decline in the PF-10 measurement over two intervals 1) 3 to 15 months following cancer diagnosis, encompassing treatment and early recovery, and 2) 3 to 27 months following cancer diagnosis, in order to detect sustained recovery versus persistent decline. Cox-proportional hazards regression was used to examine association between survival and decline in PF-10 scores. Results: A large (> 0.8 SD) decline in PF-10 scores from 3 to 27 months predicted shorter 10 year survival (HR=1.37, 95% CI 1.07-1.74). Persistent decline at 27 months was associated with less education, higher baseline PF-10, increased comorbidity, and lack of exercise at baseline. Conclusions: Older women with breast cancer who experience a large and persistent decline in PF-10 are at increased mortality risk. Future research should examine the value of clinical assessment of physical function as a marker for mortality and test interventions to prevent decline in physical function to improve post-treatment survival outcomes.
Standardization of Ki-67 assessment for breast cancer patients with preoperative endocrine therapy.
Authors: Mizuno Yoshio , Takayanagi Hiroyuki , Abe Hiroaki , Sato Kazuhiko 
Published: March 2020

e11007 Background: Change in Ki-67 levels is a predictive marker of breast cancer, and it has been widely investigated in patients treated with preoperative endocrine therapy. Several studies have compared Ki-67 expression in untreated specimens obtained by core needle biopsy (CNB) and surgery. We conducted a retrospective study to assess Ki-67 expression between these two specimen types. Methods: 307 patients underwent primary operations for early breast cancer at Tokyo-West Tokushukai Hospital from August 2008 to October 2011. Among them, 193 patients who underwent CNB prior to the operation were enrolled. Patients with ductal carcinoma in situ and those undergoing neoadjuvant chemotherapy were excluded. A cutoff value of 20% was used as the Ki-67 positive criterion. We also examined ER, PgR, and HER2 expression and compared it with Ki-67 expression. Statistical significance for concordance rates between the two types of specimens was evaluated by Wilcoxon t-test. To evaluate the consequences of formalin and genetic heterogeneity, parameters such as operative method and tumor size were analyzed using chi-square test. We reexamined Ki-67 expression in the central laboratory among the Ki-67 discordant group to evaluate the discordance between the pathologist’s judgments. Results: The Ki-67 expression concordance rate between the two types of specimens was 77.7%, which was significantly lower than that for ER, PgR, and HER2 expression at 94.8%, 88%, and 91%, respectively. No significant differences in the operative method (mastectomy vs. breast conserving surgery) or tumor size (≤2cm vs. >2cm) were observed between the groups. We reexamined Ki-67 expression in the Ki-67 discordant group and found that the Ki-67 concordance rate had improved to 93.8%. Conclusions: The Ki-67 expression concordance rate between the two types of specimens was significantly lower than that of ER, PgR, and HER2 expression. However, a reexamination of Ki-67 expression in the central laboratory revealed no significant difference, suggesting the need for a standard pathological assessment of Ki-67 expression to clinically use Ki-67 as a predictive marker.
Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.
Authors: Dizdar Omer , Arslan Cagatay , Eren Tulay , Yalcin Selim , Kucukoztas Nadire , Aksoy Sercan , Rahatli Samed , Sener Dede Didem , Altundag Ozden , Zengin Nurullah , Ozyilkan Ozgur , Altundag Mustafa Kadri 
Published: March 2020

e11011 Background: As life expectancy has steadily increased, more patients >80 yo are diagnosed with breast cancer. Data on the tumor biology, treatment choices, and outcomes are limited in this “oldest old” patient population. We herein present a multicenter retrospective analysis of octogenarian breast cancer patients including patient and tumor characteristics, treatment outcomes and survival. Methods: Patients >80 years of age who were diagnosed with breast cancer were retrospectively evaluated in 4 different cancer centers. Demographic features, tumor characteristics, treatment regimens and patient outcomes in terms of DFS and OS were analyzed. Results: A total of 83 patients were identified. Results were summarized in the table. Median age was 82. 69 (83%) had at least one co-morbid disease. Chemotherapy and radiotherapy were utilized in 15 (18%) and 21 (25%) of the patients, respectively, while endocrine treatment was given in 89% of the HR(+) patients. Median follow up was 22 months (range 1-181 months). Ten patients relapsed on follow up and 20 patients died. One of the relapses was locoregional and 9 were distant relapses. Median DFS was 68 months. Five-year OS was 61.9%. Conclusions: Breast cancer in octogenarian patients more likely seems to be low grade and hormone receptor positive. Adjuvant chemotherapy and radiotherapy were utilized infrequently. However, overall survival is fairly well with more than half of the patients alive for >5 years. [Table: see text]
Incidence of chemotherapy (CT)-induced amenorrhea in premenopausal patients (pts) with breast cancer (BC) following adjuvant anthracycline (A), cyclophosphamide (C), and taxane (T).
Authors: Basso Enrico , Rossi Luigi , Tomao Federica , Papa Anselmo , Zaccarelli Eleonora , Spinelli Gian Paolo , Lo Russo Giuseppe , Zoratto Federica , Giordani Erika , Alberti Antonio Maria , Verrico Monica , Strudel Martina , Pasciuti Giulia , Stati Valeria , Rinaldi Giulia , Tomao Silverio 
Published: March 2020

e11039 Background: CT may induce amenorrhea or menopause to a variable extent. These side-effects may impair or impede fertility, cause sexual dysfunction, bone loss and menopausal symptoms in many women. We analyzed incidence of amenorrhea in premenopausal pts affected by BC treated with CT. Methods: In this retrospective study we evaluated the incidence of amenorrhea in 24 premenopausal BC pts (43 median age years) treated with adjuvant A + C +/- T based CT. Overall population (OP) had regular menstrual cycle and no pts began hormone therapy, at the same time. Results: 10 pts (42%) received only A + C, 6 pts (25%) received A + C + T, 8 pts (33%) received A + C and after T. In 22 pts (92%) amenorrhea appeared during CT; in particular, 9/10 pts (90%) treated with A + C , 5/6 pts (83%) with A + C + T and 8/8 pts (100%) with A + C and after T. In OP amenorrhea appeared during first three cycles of CT in 18 pts (82%) and particularly 7 pts (32%) after 1 cycle, 7 pts (32%) after 2 cycles, 4 pts (18%) after 3 cycles and 4 pts (18%) in subsequent doses. Amenorrhea occurred within the first two doses of treatment in 14/22 pts (64%); in 6/9 pts (66.7%) treated with A + C, in 4/5 pts (80%) with A + C + T and in 4/8 (50%) with A + C and after T. In 7 pts (32%), median age 40 years, at the end of CT reappeared menstrual cycle. Conclusions: In our small experience the incidence of amenorrhea during CT was extremely high and there are no differences between subgroups undergoing to CT with A + C alone or combined with T. In the group of pts in which T were given concomitant with A and C, amenorrhea occurred earlier than the other two groups. Menstrual cycle reappeared at the end of CT in younger pts.
An aggressive histologic phenotype in young breast cancers in India: A correlational study.
Authors: Hazarika Diganta , Nandini Marysingh , Prabhudesai Shilpa A. , Raghavendra Rao M. , Ajaikumar Basavalinga S 
Published: March 2020

e11043 Background: Breast cancer patients younger than 40 years are known to have an aggressive disease than their older counterparts. In this correlational study involving Indian women with breast cancer; we analyzed if age is related to an aggressive histopathologic phenotype and biomarker expression. Methods: Paraffin embedded tissue blocks of hundred chemotherapy naive breast cancer patients with a diagnosis of invasive breast carcinoma were stratified for age group (less than forty and above forty years) equally from the hospital biorepository. Tissue samples were analyzed for pathological stage, histological type, ER, PR and Her2 Neu receptor status, and expression of biomarkers such as Ki67, EGFR and P53 using immunohistochemistry. Data were analyzed using Chisquare test for proportions. Results: Younger age group had significantly higher grade (p=0.03), higher incidence of solid (p=0.04) and micropapillary type DCIS (p=0.004), ER negativity (p=0.04), higher proliferation rate as indicated by over expression of Ki 67 (p=0.03) and triple negativity (p= 0.03) indicating an aggressive histological phenotype compared to older age group. Conclusions: Results suggest that younger breast cancer patients have an aggressive histological phenotype that may affect treatment response. Future studies should explore relationship of these biomarkers to survival and treatment outcomes.
Correlation of HER2/neu expression by real-time qRT-PCR in the peripheral blood of locoregional breast cancer patients with time to progression.
Authors: Kuniyoshi Renata Kelly , Vilas Boas Viviane , Alves Beatriz da Costa Aguiar , Maeda Patricia Hikari , Colo Anna Estela Luiza , Gehrke Flavia de Sousa , Fonseca Fernando L. A. , Del Giglio Auro 
Published: March 2020

e11059 Background: HER2/neu is a membrane receptor overexpressed in about 20% of Breast Cancer (BC) patients which can be targeted by several agents. As an epithelial marker it can also be detected by qRT-PCR in the peripheral blood (PB) of BC patients reflecting the presence of circulating tumor cells (CTCs). Objectives: Evaluate the prognostic impact of Her2/neu expression detection in the PB of BC patients. Methods: We performed qRT-PCR for HER2/neu serially at entry into the study and at every 3 months intervals for up to 2 years in every patient. Our qRT-PCR used primers described in Ferreira et al, 2010. In our hands this method could detect 1 MCF-7 cell diluted in 1x104 mononuclear cells and had a specificity of 83% (4/22 normal women controls had a positive test). Results: from 02/20/08 to 02/09/10 we included 41 patients with a histopathological diagnosis of BC with a mean age of 54 years (range 29 to 83 years); 55% post-menopausal; stages I:12%, II:41% and III:46%; 58% and 51% were ER+, 64% PR+, and 25% cerb2 positive (+++). The patients were treated with adjuvant and 41% with neoadjuvant chemotherapy with anthracycline regimens including anthracyclines in 88% and taxanes in 75%. With a mean follow up of 28 months, only HER2/neu expression at study entry as a continuous variable (HR = 1.125 95% CI: 1.021 – 1.238) and disease stage (HR = 6.34 95% CI 1.30 – 30.82) correlated significantly with time to progression by multivariate analysis. HER2/neu expression did not correlate with HER2/neu tissue expression. Conclusions: HER2/neu expression by Real Time RT-PCR in the PB of BC patients is a potential new prognostic factor for BC patients with locorregional disease.
A retrospective study of inflammatory breast cancer patients from seven hospitals in the United Kingdom.
Authors: Rafii Saeed , Poole Christopher John , Francis Adele , Chaudhri Shalini , Rea Daniel 
Published: March 2020

e11062 Background: Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterised by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d’orange. It is estimated that between 1-4 % of all newly diagnosed breast cancer patients in the United Kingdom have IBC. Methods: We retrospectively identified 51 patients who were treated for IBC at 7 hospitals in the West midlands area of the United Kingdom between 1997 and 2011. Data including patients’ demographics, clinical, radiological and histopathological characteristics were collected from electronic clinical records. The test for HER-2 over-expression was not carried out routinely before 2002, therefore HER-2 status of such patients were assessed retrospectively on the archived tissues. A cox regression analysis was used for statistical assessment of survival and prognostic factors. Results: Median age at diagnosis was 55 years (range 34-83 yrs). Median overall (OS) and progression free survival (PFS) were 32 months (range 7-97 months) and 27 months (range 2-53 months) respectively. The 3–year survival rate for the entire cohort was 32%. Majority of patients were ER and HER-2 positive (49% and 52% respectively). The rate of complete pathological response (pCR) after neoadjuvant chemotherapy was 14%. All cases who had achieved pCR were HER-2 positive who had received anti HER-2 treatment during the neoadjuvant chemotherapy. The OS for the HER-2 positive patients with pCR was not statistically different from the whole cohort (49 vs 32 months, p=0.09) or from the patients with residual disease (49 vs 26 months, p=0.13). Although the triple negative IBC patients consisted 20% of the cohort, no patients in this group had achieved pCR. The OS and PFS for the triple negative patients were 20 and 14 months respectively. Although the rate of pCR was higher in patients treated with taxane compared to those treated with anthracycline containing chemotherapy (35% vs 7%), there was no significant difference in OS between either of these regimens (29 vs 27 months). Conclusions: HER-2 positive IBC patients had higher rate of achieving pCR after neo-adjuvant anti HER-2 therapy. However higher rate of pCR did not improve the OS.
FcGR2A genotype and change in gene expression of effecter cells in peripheral blood after administration of trastuzumab (T).
Authors: Shimizu Chikako , Mogushi Kaoru , Koizumi Fumiaki , Tamura Kenji , Yunokawa Mayu , Fujiwara Yasuhiro , Tanaka Hiroshi 
Published: March 2020

e11065 Background: We have previously reported that FcGR2A polymorphisms were associated with clinical outcome of trastuzumab (T) in both neoadjuvant and metastatic settings in patients (pts) with HER2-positive breast cancer (Tamura et al, Ann Oncol 2011). We explored if antibody-dependent cell-mediated cytotoxicity (ADCC) can be observed as a change in gene expression of PBMC (effecter cells of ADCC) in patients receiving T according to FcGR2A phenotypes. Methods: FcGR2A genotypes in 34 patients with HER2-positive metastatic breast cancer were determined in the previously reported prospective study (Tamura et al, Ann Oncol 2011). All pts received single agent T (Starting dose 4mg/kg, maintenance dose 2mg/kg) as the first-line treatment for metastatic breast cancer. PBMC was purified from peripheral blood collected before T, at 1 wk and 8 wk of weekly T. Total RNA was extracted from PBMC and gene expressions were measured using Affimetrix GeneChip Human Genome U133 Plus 2.0 array. Gene set enrichment analysis (GSEA) ( www.broadinstitute.org/gsea ) using KEGG pathway DB was carried out to explore differentially expressed gene sets (GSs) after 1wk and 8 wk administration of T compared to baseline. GSs with significance level of p<0.05 and FDA<0.25 were considered statistically significant. Results: There were 15 and 19 patients with FcG2A- 131 HH and HR/RR genotypes, respectively. There were no significant GSs differentially expressed at 1 wk compared to baseline in both HH and HR/RR cohorts. 11 GSs were differentially expressed at 8 wk in HH cohort, whereas there were no significant GSs differentially expressed at 8wk in HR/RR cohort. The upregulated GSs at 8 wk in HH cohort included KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICIY and KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION. Conclusions: Differential pharmacogenomic response of PBMC to T according to FcG2A genotype supports the hypothesis that ADCC is associated with the mechanism of action of T.
Clinical utility and therapeutic implications of oncotype analysis in patients with breast cancer.
Authors: Williams Stephanie A. , Tatarian Talar , Teal Christine B. , McSwain Anita P. , Siegel Robert S. , Ojong-Ntui Martin , Saini Ashima , Tabbara Imad A. , Kaltman Rebecca Davidson 
Published: March 2020

e11084 Background: Oncotype DX is a 21-gene assay developed for early stage, hormone receptor positive breast cancer that generates a Recurrence Score which estimates response to chemotherapy and the likelihood of systemic recurrence at 10 years. It differentiates between patients who would benefit from chemotherapy plus hormonal therapy versus hormonal therapy alone. This study’s goal was to determine if the Recurrence Score affected clinical management at our institution and physicians’ accuracy at predicting Recurrence Scores. Methods: A retrospective review was conducted of 116 breast cancer patients treated over a 7 year period. Clinic notes, pathology reports, and additional relevant information were presented to breast surgeons, oncologists, radiation oncologists, and surgical pathologists. Individual physicians estimated recurrence risks and recommended treatment based on those estimates. The Recurrence Score was revealed and changes in therapeutic recommendations were recorded. Results: Treatment recommendations changed in 43% of patients. 29% had a change from chemotherapy followed by hormone therapy to hormone therapy alone due to a low recurrence score, while 14% initially recommended hormonal therapy were changed to chemotherapy plus hormonal therapy due to an intermediate range score. Surgical oncologists accurately predicted Recurrence Scores 52% of the time, medical oncologists 46%, radiation oncologists 45%, and surgical pathologists 15%. A nested mixed model showed that pathologists were statistically significantly worse at predicting recurrence scores than surgical oncologists, medical oncologists, and radiation oncologists. Conclusions: The Oncotype DX assay changes management of breast cancer patients at our institution, frequently downgrading the intensity of systemic therapy. Clinicians were able to accurately estimate recurrence categories about 50% of the time. We recommend the use of Oncotype DX assay along with assessment of clinicopathologic features of an individual’s disease in eligible patients to enhance the selection of appropriate adjuvant therapy.